Nurix Therapeutics (NRIX) FCF Margin (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly FCF Margin of 1082.09% for Q2 2026, down 94417.0% year-over-year from N/an in Q2 2025, and up 8.1% quarter-over-quarter from 1177.46% in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) FCF Margin (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported FCF Margin for 8 consecutive years, with 1082.09% the latest figure, recorded in Q2 2026.
- In Q2 2026, FCF Margin fell 94417.0% year-over-year to 1082.09%; the TTM figure through May 2026 stood at 807.23% (down 56287.0% YoY), while the FY2025 annual figure was 298.46%, up 2093.0% from the prior year.
- FCF Margin grew to 1082.09% in Q2 2026 per NRIX's latest filing, from 1177.46% in the prior quarter.
- Across five years, FCF Margin topped out at 210.26% in Q4 2023 and bottomed at 1177.46% in Q1 2026.
- Historically, FCF Margin has averaged 423.25% across 5 years, with a median of 363.29% in 2024.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 80763 bps — and 2026, when it sank 94417 bps.
- Nurix Therapeutics' FCF Margin stood at 597.38% in 2022, then surged by 135 bps to 210.26% in 2023, then tumbled by 255 bps to 325.4% in 2024, then tumbled by 51 bps to 492.71% in 2025, then plunged by 120 bps to 1082.09% in 2026.
- Business Quant data shows NRIX's FCF Margin at 1082.09% in Q2 2026, 1177.46% in Q1 2026, and 492.71% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | -1,082.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -1,082.09% |
| Feb 28, 2026 | -1,177.46% |
| Nov 30, 2025 | -537.40% |
| Aug 31, 2025 | -761.29% |
| May 31, 2025 | -149.44% |
| Feb 28, 2025 | -349.93% |
| Nov 30, 2024 | -382.84% |
| Aug 31, 2024 | -353.70% |
| May 31, 2024 | -344.38% |
| Feb 29, 2024 | -270.33% |
| Nov 30, 2023 | 159.01% |
| Aug 31, 2023 | -236.05% |
| May 31, 2023 | -63.73% |
| Feb 28, 2023 | -399.91% |
| Nov 30, 2022 | -597.38% |
| Aug 31, 2022 | -460.81% |
| May 31, 2022 | -312.31% |
| Feb 28, 2022 | -479.18% |
| Nov 30, 2021 | -429.60% |
| Aug 31, 2021 | -310.54% |